BlossomHill Therapeutics filed plans for an IPO targeting about $111.7 million to fund the clinical path of its EGFR-targeting drug candidate BH-30643, positioned as a potential challenger to AstraZeneca’s Tagrisso. The oncology biotech plans to sell 7.8 million shares at a proposed $15 to $17 range, with proceeds earmarked for both planned and ongoing studies. BH-30643 is in a phase 1/2 trial in NSCLC, and the company intends to use IPO proceeds to start a “potentially registrational” phase 2 trial. BlossomHill highlighted a competitive intent to address EGFR-mutant NSCLC, including patients with C797S-mediated resistance to Tagrisso or other third-generation EGFR inhibitors. The IPO filing also budgets for additional pipeline work, including BH-30236 in phase 1 for relapsed/refractory acute myeloid leukemia or higher-risk myelodysplastic syndrome and IND-enabling steps for a pan-KRAS inhibitor, BH-501284. BlossomHill previously raised $173 million before planning the public offering.